Schistosomiasis mansoni - Clinical features

Gastroenterologia y Hepatologia

Volumn 28, Issue 1, 2005, Pages 30-39

  Da Silva, L C ^a,b   Chieffi, P P ^a   Carrilho, F J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Clinical features; Diagnosis; Mansonic schistosomiasis; Schistosoma mansoni; Treatment

Indexed keywords

ANTHELMINTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; OXAMNIQUINE; PRAZIQUANTEL; PROPRANOLOL;

ACUTE DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS VARICES BLEEDING; FECES ANALYSIS; GASTROINTESTINAL HEMORRHAGE; GLOMERULOPATHY; HELMINTHIASIS; HEPATIC ARTERY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LIVER ANGIOGRAPHY; LIVER DISEASE; MIRACIDIUM; NEUROTOXICITY; PATHOPHYSIOLOGY; PNEUMONIA; PORTAL HYPERTENSION; PORTAL VEIN; PORTOSYSTEMIC ANASTOMOSIS; PROGNOSIS; RECTUM BIOPSY; REVIEW; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCLEROTHERAPY; SIDE EFFECT; SPLEEN DISEASE; TREMATODE; VIRUS HEPATITIS;

EID: 14644403730     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070382     Document Type: Article

References (95)

1. Dunn MA. Parasitic Disease. In: Schiff ER, Sorrel MF, Maddrey WC, editors. Schiff's Disease of the liver. Philadelphia: Lipincott-Raven; 1999. p. 1533-48.
2. Da Silva LC. Schistosomiasis mansoni - clinical features. In: Okuda K, Benhamou J-P, editors. Portal Hypertension. Clinical and Physiological Aspects. Tokyo: Springer-Verlag; 1991. p. 309-18.
3. Passos ADC, Amaral RS. Esquistossomose mansônica: aspectos epidemiológicos e de controle. Rev Soc Bras Med Trop 1998;31 Supl II:61-74.
4. Chieffi PP, Waldman EA. Aspectos particulares do comportamento epidemiológico da Esquistossomose mansônica no Estado de São Paulo, Brasil. Cad Saúde Públ, Rio de Janeiro 1988; 3:257-75.
5. Lambertucci JR, Serufo JC. Esquistossomose mansônica In: Gayotto LCC, Alves VAF, editores. Doenças do Fígado e Vias Biliares. Sáo Paulo: Atheneu; 2001. p. 35.
6. Giboda M, Malek EA, Correa R. Human schistossomiasis in Puerto Rico: reduce prevalence rate and absence of Biomphalaria glabrata. Am J Trop Med Hyg. 1997;57:564-8.
7. Tsang VCW, Hillyer GV, Noh J, et al. Geographic clustering and seroprevalence of schisosomiasis in Puerto Rico. Am J Trop Med Hyg. 1997;56:107-12.
8. El-Garen AA. Schistosomiasis. Digestion. 1998;59:589-605.
9. Ross AGP, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med. 2002;346:1212-20.
10. Elliott DE. Schistosomiasis. Pathophysiology, diagnosis, and treatment. Gastroenterol Clin North Am. 1996;25:599-625.
11. Coutinho AD, Domingues ALC. Esquistossomose mansoni. In: Dani R, Castro LP, editors. Gastroenterologia Clinica, 2nd ed. Rio de Janeiro: Editora Guanabara; 1988. p. 1361-86.
12. Lambertucci JR, Serufo JC, Gerspacher-Lara R, et al. Schistosoma mansoni: assessment of morbidity before and after control. Acta Tropica. 2000;77:101-9.
13. Neves J, Raso P, Pinto DM, Silva SP, Alvarenga RJ. Ischemic colitis (necrotizing colitis, pseudomembranous colitis) in acute schistosomiasis mansoni: report of two cases. Trans R Soc Trop Med Hyg. 1993;87:449-52.
14. Lambertucci JR, Rayes AAM, Barata CH, Teixeira R, Gerspacher-Lara R. Acute schistosomiasis: report on five singular cases. Mem Inst Oswaldo Cruz. 1997;92:631-5.
15. Prata A. Infection with S. mansoni. In: Jordan P, Webbe G, editors. Schistosomiasis. Epidemiology, treatment and control. London: William Heinemann; 1982. p. 105-27.
16. Cesmeli E, Vogelaers D, Voet D, et al. Ultrasound and CT changes of liver parenchyma in acute schistosomiasis. Br J Radiol. 1997;70:758-60.
17. Lambertucci JR, Pinto-Silva RA, Gerspacher-Lara R, Barata CH. Acute mansoni's schistosomiasis: sonographic features. Trans R Soc Trop Med Hyg. 1994;88:76-7.
18. Lambertucci JR. Treatment of schistomosiasis: gathering stones together. Mem Inst Oswaldo Cruz. 1995;90:161-4.
19. Da Silva LC, Carrilho FJ. Hepatosplenic schistosomiasis. Pathophysiology and treatment. Gastroenterol Clin North Am. 1992; 21:163-77.
20. Rezende SA, Lambertucci JR, Goes AM. Role of immune complexes from patients with different clinical forms of schistosomiasis in the modulation of in vitro granuloma reaction. Mem Inst Oswaldo Cruz. 1997;92:683-7.
21. Mohamed ARS, Mohamed AAK, Yasawy MI. Schistosomal colonic disease. Gut. 1990;31:439-42.
22. Da Silva LC, Pontes JF. Clinical aspects of schistosomiasis mansoni. In: Popper H, Schaffner F, editors. Progress in Liver Disease. New York: Grunne and Stratton; 1965. p. 243-52.
23. Vezozzo DCP, Farias AQ, Cerri GG, Da Silva LC, Carrilho FJ. Assessment of liver morphology and portal hemodynamics by Doppler ultrasound in the hepatosplenic and hepatointestinal forms of schistosomiasis mansoni in Brazil. To be published.
24. Smithers SR, Doenhoff MJ. Schistosomiasis. In: Cohen S, Warren KS, editors. Immunology of parasitic Infections. 2nd ed. Oxford: Blackwell; 1982. p. 527-607.
25. Bina JC. Influência da terapêutica específica na evolução da esquistossomose mansoni. Doctoral Thesis. Salvador: Faculdade de Medicina; 1977.
26. Coura JR, Conceição MJ. Correlação entre carga parasitária de S. mansoni e gravidade das formas clínicas em uma comunidade rural de Minas Gerais. Rev Soc Bras Med Trop. 1981; 14:93-7.
27. Colley DG, Garcia AA, Lambertucci JR, et al. Immune responses during human schistosomiasis: XII. Differential responsiveness in patients with hepatosplenic disease. Am J Trop Med Hyg. 1986;35:793-802.
28. Henri S, Chevillard C, Mergani A, et al. Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. Immunology. 2002;169:929-36.
29. Andrade ZA. Pathogenesis of pipe-stem fibrosis of the liver (experimental observation on murine schistosomiasis). Mem Inst Oswaldo Cruz. 1987;82:325-34.
30. Andrade ZA. Evolution and involution of hepatosplenic schistosomiasis. Mem Inst Oswaldo Cruz. 1989;84 Suppl 1:58-75.
31. Tavares-Neto J, Prata A. Family occurrence of schistosomal hepatosplenomegaly and maternal effect. Rev Soc Bras Med Trop. 1989;22:13-8.
32. Lyra LG, Rebouças G, Andrade Z. Hepatitis B surface antigen carrier state in hepatosplenic schistosomiasis. Gastroenterology. 1976;71:641-5.
33. rd ed. São Paulo: Sarvier; 2003.
34. Kamal SM, Rasenack JW, Bianchi L, et al. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology. 2001;121:646-56.
35. Pereira LM, Melo MC, Saleh MG, et al. Hepatitis C virus infection in Schistosomiasis mansoni in Brazil. J Med Virol. 1995; 45:423-8.
36. Mies S, Mori T, Larsson EJ, et al. A veia cava inferior e as veias supra-hepáticas na esquistossomose hepatoesplênica. Estudo angiográfico. Rev Hosp Clin Fac Med São Paulo. 1980;35: 136-42.
37. Mies S, Mori T, Larsson EJ, Rosa P, Raia S. Hepatic vein in mansonic schistosomiasis. Angiographic and hemodynamic pattern. Gastroenterology. 1980;78:A1314.
38. Coutinho A. Hemodynamic studies of portal hypertension in schistosomiasis. Am J Med. 1968;44:547-6.
39. Bogliolo L. A esplenoportagrafia na esquistossomose mansônica hepato-esplênica, forma de Symmers. Rev Ass Med Brás. 1957;2:263-9,
40. Carneiro JL. A circulação colateral gastroesofágica após desconexão azigoportal [doctoral Thesis]. Vitória: Universidade Federal do Espírito Santo; 1979.
41. Raia S, Mies S, Macedo AL. Portal hypertension in schistosomiasis. Clin Gastroenterol. 1985;14:57-82.
42. Morgan JS, Groszman RJ, Rojkind M, Enriquez R. Hemodynamic mechanisms of emerging portal hypertension caused by schistosomiasis in the hamster. Hepatology. 1990;11:98-104.
43. Alves CAP, Alves AR, Abreu WN, Andrade ZA. Hepatic artery hypertrophy and sinudoidal hypertension in advanced schistosomiasis. Gastroenterology. 1977;72:126-8.
44. Raia S, Mies S, Macedo AL. Surgical treatment of portal hypertension in schistosomiasis. World J Surg. 1984;8:738-52.
45. Ramos OL, Saad F, Leser WP. Portal hemodynamics and liver function in hepatic schistosomiasis. Gastroenterology. 1964;47: 241-7.
46. Condon RE, Nyhus LM, Chapman ND, Harkins HN. Portal vein and hepatic artery interaction, studies in the isolated, perfused liver. Gastroenterology. 1962;43:547-56.
47. Silveira GSM. Circulação arterial e portal do fígado esquistossomótico após esplenectomia [doctoral Thesis]. Salvador - Bahia, Faculdade de Medicina, Universidade Federal da Bahia, Brasil, 1980.
48. Mies S, Larsson E, Mori T, Rosa P, Raia S. O sistema porta e as artérias hepáticas, esplênica e mesentérica superior na esquistossomose hépato-esplênica. Estudo angiográfico. Rev Hosp Clin Fac Med São Paulo. 1980;35:121-31.
49. Lambertucci JR, Cota GF, Pinto-Silva RA, et al. Hepatosplenic schistosomiasis in field-based studies: a combined clinical and sonographic definition. Mem Inst Oswaldo Cruz, Rio de Janeiro. 2001;96:147-50.
50. Mies S, Neto OB, Beer A, et al. Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol. Dig Dis Sci. 1997;42:751-61.
51. Warren KS, Rebouças G, Baptista AG. Ammonia metabolism and hepatic coma in hepatosplenic schistosomiasis: patients studied before and after portacaval shunt. Ann Intern Med. 1965; 62:1113-33.
52. Manoukian N, Borges DR. Prealbumin, prekallikrein and prothrombin in hepatosplenic schistosomiasis: increased turnover of the clotting proteins? Rev Inst Med Trop Sao Paulo. 1984;26: 237-40.
53. Borges DR, Pardini DP, Cheter L. Estudo, em portadora da esquistossomose hepatosplenica, da protrombina e da procalicreina: efeitos da heparinização e esplenectomia [carta]. Rev Assoc Med Brás. 1989;35:39-40.
54. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1972;14:397-400.
55. Mott KE, Dixon H. Collaborative study on antigens for immunodiagnosis of schistosomiasis. Bull World Health Organ. 1982;60:729-53.
56. Da Silva LC, Hoshino-Shimizu S, Kanamura H, et al. Serum antibody changes after chemotherapy of patients with schistosomiasis mansoni. A statistical analysis. Rev Inst Med Trop Sao Paulo. 1975;17:344-9.
57. Da Silva LC, Ferri RG. Immunodiffusion studies in human schistosomiasis mansoni I. Hepatointestinal and hepatosplenic forms. Rev Inst Med Trop São Paulo. 1965;7:1-6.
58. Pinon JM, Dropsy G. Étude de l'immunité humorale dans la bilharziose humane. Interêt de I'ELIEDA (enzyme - linked - immuno - electro - diffusion assay). Bull Soc Pathol Exot. 1977;69:238-44.
59. Cerri GG, Alves VAF, Magalhaes A. Hepatosplenic schistosomiasis mansoni: ultrasound manifestations. Radiology. 1984; 153:777-80.
60. Hatz C, Jenkins JM, Ali QM, Abdel-Wahab MF, Cerri GG, Tanner M. A review of the literature on the use of ultrasonography in schistosomiasis with special reference to its use in field studies. 2. Schistosoma mansoni. Acta Trop. 1992;51:15-28.
61. Cairo Working Group. The use of diagnostic ultrasound in schistosomiasis-attempts at standardization of methodology. Acta Trop. 1992;51:45-63.
62. Martins RD, Szejnfeld J, Lima FG, Ferrari AP. Endoscopic, ultrasonographic, and US-Doppler parameters as indicators of variceal bleeding in patients with schistosomiasis. Dig Dis Sci. 2000;45:1013-8.
63. Richter J, Domingues AI, Barata CH, Prata AR, Lambertucci JR. Report of the second satellite symposium on ultrasound in schistosomiasis. Mem Inst Oswaldo Cruz. 2001;96(Suppl): 151-6.
64. Richter J, Hatz C, Haussinger D. Ultrasound in tropical and parasitic diseases. Lancet. 2003;362:900-2.
65. Homeida M, Abdel-Gadir AF, Cheever AW, et al. Diagnosis of pathologically confirmed Symmers' periportal fibrosis by ultrasonography: a prospective blinded study. Am J Trop Med Hyg 1988;38:86-91.
66. Paranagua-Vezozzo DC, Cerri GG. Duplex hemodynamic evaluation of hepatosplenic mansoni schistosomiasis. Mem Inst Oswaldo Cruz 1992;87 Suppl 4:149-51.
67. De Brito T, Nussensveig I, Carneiro CRW, Silva AMG. Schistosoma mansoni associated glomerolopathy [editorial]. Rev Inst Med Trop São Paulo. 1999;41:269-72.
68. De Brito, T Nussensveig I, Carneiro CRW, et al. Glomerular detection of schistosomal antigen by immunoelctron microscopy in human mansoni schistosomiasis. Int J Surg Pathol. 1999;7:217-25.
69. Nussenzveig I, De Brito T, Carneiro CR, Silva AM. Human Schistosoma mansoni-associated glomerulopathy in Brazil. Nephrol Dial Transplant. 2002;17:4-7.
70. Da Silva LC, De Brito T, Camargo ME, De Boni DR, Lopes JD, Gunji J. Kidney biopsy in the hepatosplenic form of infection with Schistosoma mansoni in man. Bull World Health Organ. 1970;42:907-10.
71. Sobh MA, Moustafa FE, Sally SM, Deelder AM, Ghoniem MA. Characterization of kidney lesions in early schistosomal-specific nephropathy. Nephrol Dial Transplant. 1988;3:392-8.
72. Andrade ZA, Van Marck E. Schistosomal glomerular disease (a review). Mem Inst Oswaldo Cruz. 1984;79:499-506.
73. De Brito T, Gunji J, Camargo ME, Penna DO, Da Silva LC. Advanced kidney disease in patients with hepatosplenic Manson's schistosomiasis. Rev Inst Med Trop Sao Paulo. 1970;12: 225-35.
74. Falcao HA, Gould DB. Immune complex nephropathy i schistosomiasis. Ann Intern Med. 1975;83:148-54.
75. Hoshino-Shimizu S, De Brito T, Kanamura H, et al. Human schistosomiasis: S. mansoni antigen detection in renal glomeruli. Trans Roy Soc Trop Med Hyg. 1976;70:492-6.
76. Martinelli R, Pereira LJ, Brito E, Rocha H. Clinical course of focal segmental glomerulosclerosis associated with hepatosplenic schistosomiasis mansoni. Nephron. 1995;69:131-4.
77. Da Silva LC, Sette Jr H. Pulmonary and renal lesions after oxamniquine in patients with hepatosplenic schistosomiasis mansoni. Gastroenterology. 1978;74:A1118.
78. Da Silva LC, Zeitune JMR, Rosa-Eid LM, et al. Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine. Rev Inst Med Trop Sao Paulo. 1986;28:174-80.
79. World Health Organization. Control de la Esquistomiasis: informe de un Comité de Expertos de la OMS. Serie de Informes Técnicos 728. Geneva, 1985.
80. Da Silva LC, Sette Jr H, Christo CH, et al. Praziquantel in the treatment of the hepatosplenic form of Schistosomiasis mansoni. Arzneimittelforschung. 1981;31:601-3.
81. Zwingenberger K, Richter J, Vergetti JG, Feldmever H. Praziquantel in the treatment of hepatosplenic schistosomiasis: biochemical disease markers indicate deceleration of fibrosis and diminution of portal flow obstruction. Trans R Soc Trop Med Hyg. 1990;84:252-6.
82. Da Silva LC. Portal hypertension in schistosomiasis: pathophysiology and treatment. Mem Inst Oswaldo Cruz. 1992;87 Suppl IV:183-6.
83. Sakai P, Boaventura S, Ishioka S, Mies S, Sette Jr H, Pinotti HW. Sclerotherapy of bleeding esophageal varices in schistosomiasis. Comparative study in patients with and without previous surgery for portal hypertension. Endoscopy. 1990;22:5-7.
84. Spence RAJ. Prevention of recurrent bleeding: nonshunting surgery. In: Okuda K, Benhamou JP, editors: Portal Hypertension, clinical and physiological aspects. Tokyo: Springer-Verlag; 1991. p. 533-47.
85. Scarin SK, Grozmann RJ, Mosca PG, et al. Propranolol ameliorates the development of portal systemic shunt in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest. 1991;87:1032-6.
86. Mies S, Pereira MB, Orlando CD, Sette M, Raia S. Propranolol na prevenção da recidiva de hemorragia digestiva em pacientes com esquistossomose hepatoesplenica. AMB Rev Assoc Med Bras. 1988;34:24-8.
87. Neto OB, Beer A Jr, Baia CE, et al. Systemic and hepatic hemodynamics in hepatosplenic manson's schistosomiasis with and without propranolol. Dig Dis Sci. 1997;42:751-61.
88. Strauss E, Lacet CM, Honain NZ, Santos WR, Tramonti R, Albano A. Partial results of a controlled randomized trial comparing propranolol and sclerotherapy for the treatment of portal hypertension. Dig Dis Sci. 1986;31:131S.
89. El Torabi H, El Amin AA, Shaeen M, Woda AS, Homeida M, Harron DN. Propranolol reduces mortality in patients with portal hypertension secondary to schistosomiasis. Ann Trop Med Parasitol. 1994;88:493-500.
90. Maurizio R, Eugenio C, Roberto PR. Results of sclerotherapy for bleeding esophageal varices in patients with schistosomal liver disease. A retrospective study. Hepatogastroenterology. 2000;47:424-8.
91. Cordeiro F. Variceal sclerosis in schistosomotic patients: A five-year follow-up study. Gastrointest Endosc. 1990;36:475-8.
92. Da Silva LC, Strauss E, Gayotto LCC et al. A randomized trial for the study of the elective surgical treatment of portal hypertension in mansonic schistosomiasis. Ann Surg. 1986;204:148-53.
93. Raia S, Da Silva LC, Gayotto LCC, Forster SC, Fukushima J, Strauss E. Portal hypertension in schistosomiasis: a long-term follow-up of a randomized trial comparing three types of surgery. Hepatology. 1994;20:398-403.
94. Conn HO. A randomized comparison of three types of surgery in schistosomal portal hypertension: many fewer answers than quentions [editorial]. Hepatology. 1994;20:526-8.
95. Carrilho FJ, Chieffi PP, Da Silva LC. Prevention of Schistosomiasis. IASL-EASL Postgraduate course. Prevention and Intervention in Liver Disease. Madrid: Spain; 2002. p. 109-19.